Table 2.

Sample information (N=23).

Study	Year	Sample size, n	Mean age (y)	Age range (y)	Ambulatory	RTTa severity	Waitlist control
Bumin et al [31]	2003	1	11	N/Ab	1 yes	—c	—
Schaefer-Campion and Johnson [32]	2015	1	5	N/A	1 yes	—	—
Lerma-Castaño et al [33]	2024	1	10	N/A	1 yes	—	—
Downs et al [34]	2018	12	3	2-6	9 yes; 3 no	—	Crossover design
Downs et al [35]	2023	39	20	6-41	39 yes; 0 no	—	Control group
Imamura et al [36]	2020	1	17	N/A	1 yes	—	N/A
Kapel et al [18]	2022	5	31	17-44	3 yes; 2 no	—	N/A
Lotan et al [37]	2004	4	10	8-11	4 yes	—	Multiple baseline
Lotan and Barmatz [38]	2009	1	5	N/A	1 no	—	—
Lotan et al [39]	2015	1	—	N/A	1 yes	—	—
Lotan et al [40]d	2021	42	15.7	2-41	21 yes; 21 no	Moderate to severe	Multiple baseline
Lotan et al [41]	2021	5	9	5-18	4 yes; 1 no	—	—
Panzeri et al [42]	2024	9	8.6	6-44	9 yes	Moderate to severe	—
Rocco et al [43]	2023	1	8	N/A	1 yes	—	—
Romano et al [44]d	2022	42	15.7	2-41	21 yes; 21 no	Moderate to severe	Multiple baseline
Romano et al [45]	2022	20	15.6	3-39	Unknown	Moderate to severe
Romano et al [46]	2022	13	17.9	3-35	8 yes; 5 no	Mild to severe	Multiple baseline
Romano et al [47]	2025	20	11.5	6-16	9 yes; 11 no	Mild to severe	Multiple baseline
Stahlhut et al [48]	2020	14	18.7	5-48	9 yes; 5 no	Moderate to severe	Multiple baseline
Stasolla and Caffo [49]	2013	2	9.5	2-17	2 yes	—	Multiple baseline
Stasolla et al [50]	2018	5	15	13-17	5 yes	Severe	Multiple baseline
Escobar Torres et al [51]	2019	3	Unknown	4-7	2 yes; 1 no	—	—
Zwilling et al [52]d	2022	42	15.7	2-41	21 yes; 21 no	Moderate to severe	Multiple baseline

^aRTT: Rett syndrome.

^bN/A: not applicable.

^cIndicates staggered introduction of the intervention to establish experimental control.

^dIndicates overlap in publications stemming from a single sample.